US4305940A - Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom - Google Patents
Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom Download PDFInfo
- Publication number
- US4305940A US4305940A US06/207,902 US20790280A US4305940A US 4305940 A US4305940 A US 4305940A US 20790280 A US20790280 A US 20790280A US 4305940 A US4305940 A US 4305940A
- Authority
- US
- United States
- Prior art keywords
- pharmaceutically acceptable
- sub
- compound according
- acceptable salt
- dimethylanilide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to benzamides and more specifically to compounds of formula I: ##STR2## which carry a basic group.
- formula I hereinabove,
- R CH 3 , Cl or COOCH 3 ;
- R 1 is a dialkylamine, pyrrolidine, piperidine, or morpholine residue
- CH 2 --R 1 may be in position ortho, meta, or para with respect to the carbonyl group
- the compounds of formula I exhibit local anaesthetic properties so that they are useful for topical application, filtration, conduction, regional block, etc., and also agents against fibrillation.
- the invention also relates to pharmaceutical compositions having a local anaesthetic activity or anti-arrhythmic activity which contain as the active ingredient at least one compound of formula I or its salts with pharmaceutically acceptable acids.
- the invention also relates to a method of preparation for the benzamides of formula I which consists of reacting under conditions well-known in the art, a compound of formula II: ##STR3## in which R has the meaning indicated hereinabove with an amine of formula III:
- the amides of formula I may be prepared from a derivative of benzoic acid which already contains the basic group and which also contains a chemically active substituent, of formula IV: ##STR4## in which R' has the same meaning defined hereinabove and X is chlorine or alkoxy or carbethoxycarbonyloxy or another active residue by reaction under conditions well-known in the art with an aniline of formula V: ##STR5## in which R has the meaning defined hereinabove.
- the compounds of formula I may be converted by methods well-known in the art into the corresponding salts with pharmaceutically acceptable acids, both inorganic, for instance, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc., and organic, for instance, citric acid, tartaric acid, malic acid, maleic acid, etc.
- pharmaceutically acceptable acids both inorganic, for instance, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc.
- organic for instance, citric acid, tartaric acid, malic acid, maleic acid, etc.
- the compounds according to the present invention exhibit a very high local anaesthetic activity and also anti-arrhythmic activity.
- the toxicological and pharmacological properties of the compounds of formula I will be manifest on the basis of the following work.
- the data reported hereinbelow relate in every instance to the hydrochloride salts of the individual compounds.
- Acute toxicity has been determined in Swiss rats by the intraperitoneal injection of the compounds dissolved in physiological saline solution. The behavior of the animals has then been followed for a period of five days.
- the DL 50 has been determined according to the method of I. T. Litchfield and F. Wilcoxon, (J. Pharmacol. Exper. Ther., 96, 99, 1949). The results are reported in Table II, second column. The compound numbers in Table II correspond to the numbers in Table I.
- the surface anaesthesia has been determined in rabbits according to the method of M. R. A. Change and H. Lobstein (J. Pharmacol. Exper. Ther., 82, 203, 1944).
- the compounds dissolved in physiological saline solution of pH 7 were injected into the conjunctival sac and the corneal reflux was induced with the brush of Frey six times at intervals of five minutes for a total period of 40 minutes.
- the extent of surface anaesthesia has been measured quantitatively by measuring the sum of the instances during which the animals did not blink during a period of 40 minutes on 48 possible blinks.
- the anaesthesia by infiltration has been determined in guinea pigs according to the method of E. Bulbring and I. Wajda, (Journal of Pharmacol. Exper. Ther. 85, 78, 1945).
- four doses of the substance in 0.25 cc of physiological saline solution is injected subcutaneously on the back after removal of hair. After five minutes, each animal is punctured six times at intervals of 3-5 minutes.
- the test was repeated every five minutes for a period of 30 minutes.
- the extent of anaesthesia by infiltration was measured quantitatively by determining the sum of the instances in which the animal remained immobile during the thirty minute period on 36 possible blinks.
- Anaesthesia by conduction has been determined on frogs according to the method of E. Bulbring and I. Wajda (Journal Pharmacol. Exper. Ther., 85, 78, 1945).
- the compounds dissolved in physiological saline solution are introduced into the cavity obtained by a transversal incision in the abdomen and separating the viscera in order to expose the lumbar plexus.
- the period of time necessary to eliminate the reflux of contraction of the lower limbs stimulated by immersion of both posterior legs into hydrochloric acid of increasing concentration between 0.05-0.1-0.2 N for a period not in excess of ten seconds, at intervals of one minute is determined.
- the extent of anaesthesia of conduction has been determined by measuring the period of time required for each compound in three different concentrations, 0.2%-0.5%-1.0% in order to abolish the reflex of contraction with the concentration of hydrochloric acid indicated hereinabove.
- CE 50 represents the concentration in percent which permits to achieve 50% of the total responses with respect to the total number of applied stimulating agents in the tests of surface anaesthesia and infiltration anaesthesia.
- the compounds of the present invention exhibit anti-arrhythmic properties and local anaesthestic properties with a mechanism of action similar to mexiletine and tocainide which reduce the number of channels for sodium because they particularly influence the rapid response and the slow sodium-dependent response, (O. Hauswirth and B. H. Singh: Pharmacology Review, 30, 5, 1978).
- Vials of 2 cc capacity are filled with a sterile aqueous solution of the compounds according to the present invention in a 1-2% concentration, with or without an epinephrine or norepinephrine in the ratio of 1:80,000 or 1:50,000 together with 0.1% sodium metabisulfite, (for conditions of the oral cavity, tongue, teeth, etc.).
- Vials of 2,5,10 cc capacity and bottles of 50 cc capacity are used containing aqueous sterile solutions of the compounds according to the present invention in the concentration of 0.5%-10% (by the endovenous and intramuscular route).
- formulations contain the compounds according to the present invention in the concentration of 1%-5% with or without an antiseptic and are provided in the form of:
- a gel with excipients for instance, sodium carboxymethylcellulose or carboxypolymethylene with triethanolamine and water (for endoscopic handling).
- a cream for instance used with excipients such as cetyltrimethylammonium bromide, cetyl alcohol, white wax, sodium lauryl sulfate, glycerine, and water. These creams are particularly suitable in cases of burns, erythema due to the sun rays, rashes, anogenital itching, and insect bites.
- Hydrophilic ointment (with excipients such as polyglycols, stearyl alcohol, sodium laurylsulfate, glycerine, water). These ointments are used in the case of burns, erythema caused by sun rays, rashes, anogenital itching, or insect bites.
- Viscous solutions (The excipients may be sodium carboxymethylcellulose in water). These solutions are suitable in case of irritation and inflammation of the oral cavity and the pharynx.
- the excipients may be for instance, menthol, cineole, propylene glycol, together with propellants) for broncoscopic use.
- Collyrium (The excipients may be methylcellulose in water) for corneal anaesthesia without mydriasis.
- the excipients may be triglycerides of fatty acids or polyethylene glycols to be used in case of hemorrhoids, anal itching, anal and rectum conditions, and tenesmus).
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Benzamides of formula I ##STR1## are described, in which R=CH3, Cl or COOCH3 ; R' is a member selected from the group of dialkylamine, pyrrolidine, piperidine, and morpholine radicals. CH2 R' is in position ortho, meta, or para with respect to the carbonyl group; and their salts thereof with pharmaceutically acceptable acids are described. The novel compounds exhibit local anaesthetic and antiarrhythmic activity.
Description
The present invention relates to benzamides and more specifically to compounds of formula I: ##STR2## which carry a basic group. In the formula I hereinabove,
R=CH3, Cl or COOCH3 ;
R1 is a dialkylamine, pyrrolidine, piperidine, or morpholine residue;
CH2 --R1 may be in position ortho, meta, or para with respect to the carbonyl group; and
Salts thereof with pharmaceutically acceptable acids.
The compounds of formula I exhibit local anaesthetic properties so that they are useful for topical application, filtration, conduction, regional block, etc., and also agents against fibrillation.
The invention also relates to pharmaceutical compositions having a local anaesthetic activity or anti-arrhythmic activity which contain as the active ingredient at least one compound of formula I or its salts with pharmaceutically acceptable acids.
The invention also relates to a method of preparation for the benzamides of formula I which consists of reacting under conditions well-known in the art, a compound of formula II: ##STR3## in which R has the meaning indicated hereinabove with an amine of formula III:
R'H
in which R' has the same meaning defined hereinabove. According to an alternative procedure, the amides of formula I may be prepared from a derivative of benzoic acid which already contains the basic group and which also contains a chemically active substituent, of formula IV: ##STR4## in which R' has the same meaning defined hereinabove and X is chlorine or alkoxy or carbethoxycarbonyloxy or another active residue by reaction under conditions well-known in the art with an aniline of formula V: ##STR5## in which R has the meaning defined hereinabove.
The examples below illustrate the process according to the present invention.
(a) 2,6-Dimethylanilide of 4-chloromethylbenzoic acid
A solution of 18.9 g of 4-chloromethylbenzoyl chloride in 200 cc of acetone is treated with 12.1 g of m-xylidine and 30 g of anhydrous K2 CO3. The mixture is heated at reflux for two hours. After cooling, the reaction mixture is filtered, the solvent is distilled off and the residue is recrystallized from ethanol.
Yield: 16.2 grams;
Melting Point: 160°-163° C.
Analysis, Calculated for: C16 H16 ClNO: Found: C 70.09; H 5.75; Cl 12.75; N 5.21; Calcd: C 70.18; H 5.89; Cl 12.96; N 5.12.
Application of an analogous method has provided the following intermediates:
2,6-dimethylanilide of 2-chloromethylbenzoic acid,
Melting Point: 170°-172° C. (from ethanol);
2,6-dimethylanilide of 3-chloromethylbenzoic acid,
Melting Point: 130°-132° C. (from ligroin);
2-methyl-6-chloroanilide of 2-chloromethylbenzoic acid,
Melting Point: 142°-144° C. (from ethanol);
2-methyl-6-carbomethoxyanilide of 2-chloromethylbenzoic acid,
Melting Point: 122°-125° C. (from ethanol);
(b) 2,6-Dimethylanilide of 4-piperidinomethyl-benzoic acid
A solution of 2.7 grams of 2,6-dimethyl-p-chloromethylbenzanilide in 200 cc of benzene is treated with a slight excess of piperidine and the mixture is heated under reflux for 4-5 hours. The mixture is cooled. The benzene phase is washed with water, then is concentrated to dryness and the residue recrystallized from ligroin. Yield: 2.1 grams; Melting Point: 176°-177° C.
Analysis: Calculated for: C21 H26 N2 0: Found: C 78.82; H 8.25; N 8.39; Calcd: C 78.81; H 8.13; N 8.69;
Hydrochloride, white crystalline solid, Melting Point: 270°-272° C.
2,6-Dimethylanilide of 2-diethylaminomethylbenzoic acid
A solution of 2.37 grams (0.01 mole) of 2-diethylaminomethylbenzoic acid chloride in 50 cc of benzene is treated with 2.42 grams of 2,6-dimethylanilide and the mixture is refluxed on a water bath for four hours. The mixture is filtered from insoluble material, the benzene phase is washed with water and concentrated to dryness. The residue is recrystallized from ligroin
Yield: 2.5 grams (80%);
Solid white crystalline, Melting Point: 99°-101° C.
Analysis: Calculated for C20 H26 N2 0: Found: 77.42; H 8.52; N 9.00; Calc.: 77.36; H 8.45; N 9.03.
The other compounds of formula I listed in Table I are prepared by analogous methods.
TABLE I
__________________________________________________________________________
##STR6##
Melting
ANALYSIS Point of
Melting
C% H% N% the
No R CH.sub.2 R'
FORMULA
Point
calc.
Found
calc.
Found
calc.
Found
HCl
__________________________________________________________________________
Salt
1 CH.sub.3
o-CH.sub.2 NEt.sub.2
C.sub.20 H.sub.26 N.sub.2 O
99-101
77.36
77.42
8.45
8.52 9.03
9.00
162-164°
2 CH.sub.3
m-CH.sub.2 NEt.sub.2
C.sub.20 H.sub.26 N.sub.2 O
100-102
77.36
77.30
8.45
8.40 9.03
9.06
--
3 CH.sub.3
p-CH.sub.2 NEt.sub.2
C.sub.20 H.sub.26 N.sub.2 O
141-142
77.36
77.50
8.45
8.35 9.03
9.12
--
4 CH.sub.3
##STR7## C.sub.20 H.sub.24 N.sub.2 O
105-108
77.87
77.67
7.85
7.80 9.09
9.06
228-230°
5 CH.sub. 3
##STR8## C.sub.20 H.sub.24 N.sub.2 O
120-122
77.87
77.85
7.85
7.91 9.09
9.12
230-234°
6 CH.sub.3
##STR9## C.sub.20 H.sub.24 N.sub.2 O
170-172
77.87
77.92
7.85
7.95 9.05
9.19
290-292°
7 CH.sub.3
##STR10## C.sub.21 H.sub.26 N.sub.2 O
111-114
78.81
78.62
8.13
8.06 8.69
8.75
210-212°
8 CH.sub.3
##STR11## C.sub.21 H.sub.26 N.sub.2 O
118-120
78.81
78.70
8.13
8.10 8.69
8.59
252-255°
9 CH.sub.3
##STR12## C.sub.21 H.sub.26 N.sub.2 O
176-177
78.81
78.82
8.13
8.25 8.69
8.39
270-272°
10 CH.sub.3
##STR13## C.sub.20 H.sub.24 N.sub.2 O.sub.2
135-138
74.03
74.05
7.46
7.42 8.64
8.61
213-216°
11 CH.sub.3
##STR14## C.sub.20 H.sub.24 N.sub.2 O.sub. 2
108-110
74.03
74.12
7.46
7.40 8.64
8.72
172-176°
12 CH.sub.3
##STR15## C.sub.20 H.sub.24 N.sub.2 O.sub.2
156-158
74.03
74.08
7.46
7.66 8.64
8.73
276-280°
13 Cl o-CH.sub.2 NEt.sub.2
C.sub.19 H.sub.23 ClN.sub.2 O
89-91
62.87
62.77
6.39
6.41 7.72
7.80
209-213°
14 COOCH.sub.3
o-CH.sub.2 NEt.sub.2
C.sub.21 H.sub.26 N.sub.2 O.sub.3
79-81
71.14
71.20
7.40
7.30 7.91
7.82
183-185°
__________________________________________________________________________
The compounds of formula I may be converted by methods well-known in the art into the corresponding salts with pharmaceutically acceptable acids, both inorganic, for instance, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc., and organic, for instance, citric acid, tartaric acid, malic acid, maleic acid, etc.
As it has been mentioned hereinabove, the compounds according to the present invention exhibit a very high local anaesthetic activity and also anti-arrhythmic activity. The toxicological and pharmacological properties of the compounds of formula I will be manifest on the basis of the following work. The data reported hereinbelow relate in every instance to the hydrochloride salts of the individual compounds.
Acute toxicity has been determined in Swiss rats by the intraperitoneal injection of the compounds dissolved in physiological saline solution. The behavior of the animals has then been followed for a period of five days. The DL50 has been determined according to the method of I. T. Litchfield and F. Wilcoxon, (J. Pharmacol. Exper. Ther., 96, 99, 1949). The results are reported in Table II, second column. The compound numbers in Table II correspond to the numbers in Table I.
TABLE II
__________________________________________________________________________
ANAESTHESIA
DL.sub.50 Conduction
i.p. Surface Infiltration
1/t'max.
Compound
(mg/kg) CE.sub.50
DL.sub.50 /CE.sub.50
CE.sub.50
DL.sub.50 /CE.sub.50
(c = 1%)
DL.sub.50 /t'
__________________________________________________________________________
1 17.2 (18.3-16.3)
0.50
34 0.25
69 0.33 6
2 67.0 (75.0-59.8)
0.41
163 0.23
291 1.00 67
3 82.5 (87.9-77.4)
4.78
17 8.02
10 0.11 9
4 55.0 (71.1-42.0)
1.85
30 0.34
162 1.00 55
5 225 (249-203)
24.12
9 8.01
28 1.00 225
6 215 (236-195)
16.03
13 4.50
48 0.50 107
7 87.1 (92.5-81.8)
0.30
290 0.21
414 1.00 87
8 205 (226-186)
2.82
73 0.36
569 0.20 41
9 210 (232-190)
1.92
109 0.28
750 0.09 19
10 230 (257-207)
6.86
34 2.34
98 0.09 21
11 260 (284-238)
11.90
22 0.95
273 0.11 29
12 230 (255-208)
2.82
82 2.25
102 0.25 57
13 16.3 (17.6-14.9)
0.60
27 0.28
58 1.00 16
14 24.7 (26.9-22.6)
0.41
60 0.43
57 0.20 5
Lidocaine
142 (160-131)
2.30
62 0.75
189 0.09 13
__________________________________________________________________________
As it is clear from the data in the Table above, a substantial number of the compounds of formula I is substantially less toxic than lidocaine, (α-diethylamino-2,6-dimethyl-acetanilide).
The surface anaesthesia has been determined in rabbits according to the method of M. R. A. Change and H. Lobstein (J. Pharmacol. Exper. Ther., 82, 203, 1944). The compounds dissolved in physiological saline solution of pH 7 were injected into the conjunctival sac and the corneal reflux was induced with the brush of Frey six times at intervals of five minutes for a total period of 40 minutes. The extent of surface anaesthesia has been measured quantitatively by measuring the sum of the instances during which the animals did not blink during a period of 40 minutes on 48 possible blinks.
The anaesthesia by infiltration has been determined in guinea pigs according to the method of E. Bulbring and I. Wajda, (Journal of Pharmacol. Exper. Ther. 85, 78, 1945). In each experiment, four doses of the substance in 0.25 cc of physiological saline solution is injected subcutaneously on the back after removal of hair. After five minutes, each animal is punctured six times at intervals of 3-5 minutes.
The test was repeated every five minutes for a period of 30 minutes. The extent of anaesthesia by infiltration was measured quantitatively by determining the sum of the instances in which the animal remained immobile during the thirty minute period on 36 possible blinks.
Anaesthesia by conduction has been determined on frogs according to the method of E. Bulbring and I. Wajda (Journal Pharmacol. Exper. Ther., 85, 78, 1945). The compounds dissolved in physiological saline solution are introduced into the cavity obtained by a transversal incision in the abdomen and separating the viscera in order to expose the lumbar plexus. The period of time necessary to eliminate the reflux of contraction of the lower limbs stimulated by immersion of both posterior legs into hydrochloric acid of increasing concentration between 0.05-0.1-0.2 N for a period not in excess of ten seconds, at intervals of one minute is determined. The extent of anaesthesia of conduction has been determined by measuring the period of time required for each compound in three different concentrations, 0.2%-0.5%-1.0% in order to abolish the reflex of contraction with the concentration of hydrochloric acid indicated hereinabove.
For each compound according to the invention, comparison with lidocaine has been made, the comparison being calculated and expressed as CE50, which represents the concentration in percent which permits to achieve 50% of the total responses with respect to the total number of applied stimulating agents in the tests of surface anaesthesia and infiltration anaesthesia. By referring the values of CE50 to the values of DL50, one obtains a parameter which is analogous to the therapeutic index and which is capable of expressing the correlation between local anaesthetic activity and acute toxicity. This method of evaluation, however, cannot be applied in the case of conduction anaesthesia in frogs because the test does not give quantitative responses since the responses are of the type "everything or nothing." In this latter case, therefore, the parameter of efficacy of each compound is assumed to be the reciprocal of the maximum time at the concentration of 1%. The results are reported in Table II. On the basis of the comparison of the values, DL50 /CE50 (or DL50 /t), one notes the clear superiority of some of the compounds of formula I with respect to lidocaine. This superiority is even more clear from an examination of Table III in which the values of toxicity and activity of lidocaine arbitrarily have been made equal to one.
TABLE III
______________________________________
ANAESTHESIA
Conduction
Surface Infiltration
1/t'max.
Ac- Ac- (c = 1%)
tiv- tiv- with
Com- DL.sub.50
ity DL.sub.50 /
ity DL.sub.50 /
respect to
DL.sub.50 /
pound i.p. * CE.sub.50
* CE.sub.50
lidocaine
t'
______________________________________
1 0.12 4.60 0.55 3.00 0.36 3.6 0.46
2 0.47 5.60 2.63 3.26 1.54 11.1 5.15
3 0.58 0.48 0.27 0.09 0.05 1.2 0.69
4 0.39 1.24 0.48 2.20 0.86 11.1 4.23
5 1.58 0.09 0.15 0.09 0.15 11.1 17.31
6 1.51 0.14 0.21 0.16 0.25 5.5 8.31
7 0.61 7.66 4.68 3.57 2.19 11.1 6.69
8 1.44 0.82 1.18 2.08 3.01 2.2 3.15
9 1.48 1.20 1.77 2.67 3.97 1.0 1.46
10 1.62 0.34 0.55 0.32 0.52 1.0 1.61
11 1.83 0.19 0.35 0.79 1.44 1.2 2.15
12 1.62 0.82 1.32 0.33 0.54 2.7 4.46
13 0.11 3.83 0.43 2.68 0.31 11.1 1.23
14 0.17 5.61 1.00 1.74 0.30 2.2 0.38
Lido- 1 1 1 1 1 1 1
caine
______________________________________
* Activity with respect to lidocaine
This determination has been made in Wistar rats, anaesthetized with ethylurethane, (1 g/kg i.p.), according to the method of B. Vargaftig and J. L. Coigner (European Journal Pharmacology, 6, 49, 1969). The compounds dissolved in physiological saline solution, are injected intravenously three minutes prior to the infusion of aconitine, (10 mcg/kg/min.). The extent of anti-arrhythmic activity is determined quantitatively by determining the amount of aconitine necessary to induce ventricular arrhythmia. The data obtained are reported in Table IV. These data show that compounds 1, 13, and 14 are at least twenty times more active than lidocaine and at least ten times more active than quinidine.
TABLE IV
______________________________________
mg/kg Aconitine i.v.
Compound i.v. mcg/kg
______________________________________
1 0.6 50 ± 5
1.0 67 ± 8
3.0 69 ± 8
2 1.0 43 ± 8
3.0 77 ± 9
6.0 82 ± 9
3 1.0 38 ± 5
3.0 39 ± 6
8.0 47 ± 7
13 0.6 48 ± 6
1.0 65 ± 7
3.0 67 ± 7
14 0.6 45 ± 8
1.0 60 ± 7
3.0 81 ± 7
Lidocaine 12.5 41 ± 4
hydrochloride 25.0 54 ± 5
Quinidine 10.0 50 ± 3
sulfate 40.0 88 ± 11
______________________________________
The compounds of the present invention exhibit anti-arrhythmic properties and local anaesthestic properties with a mechanism of action similar to mexiletine and tocainide which reduce the number of channels for sodium because they particularly influence the rapid response and the slow sodium-dependent response, (O. Hauswirth and B. H. Singh: Pharmacology Review, 30, 5, 1978).
In clinical trial, preliminary tests have shown the superior anaesthestic activity and anti-arrhythmic activity with respect to lidocaine of the compounds according to the present invention which exhibit greater activity and which are more tolerated in the pharmacological tests reported hereinabove when the compounds are used in adequate formulations as indicated hereinbelow.
The following typical formulations are described hereinbelow for the purpose of illustrating the present invention.
(a) For use as a local anaesthetic:
Vials of 2 cc capacity are filled with a sterile aqueous solution of the compounds according to the present invention in a 1-2% concentration, with or without an epinephrine or norepinephrine in the ratio of 1:80,000 or 1:50,000 together with 0.1% sodium metabisulfite, (for conditions of the oral cavity, tongue, teeth, etc.).
Vials of 2,5,10,20 cc capacity and bottles containing aqueous sterile solutions of the compounds according to the present invention in the concentration of 0.25%-5% with or without epinephrine in the ratio of 1:20,000 or 1:100,000, together with 0.1% sodium metabisulfite, (for anaesthesia by infiltration or conduction, regional block, epidural and caudal, etc.)
(b) For use as an anti-arrhythmic agent:
Vials of 2,5,10 cc capacity and bottles of 50 cc capacity are used containing aqueous sterile solutions of the compounds according to the present invention in the concentration of 0.5%-10% (by the endovenous and intramuscular route).
These formulations contain the compounds according to the present invention in the concentration of 1%-5% with or without an antiseptic and are provided in the form of:
A gel, with excipients for instance, sodium carboxymethylcellulose or carboxypolymethylene with triethanolamine and water (for endoscopic handling).
A cream (for instance used with excipients such as cetyltrimethylammonium bromide, cetyl alcohol, white wax, sodium lauryl sulfate, glycerine, and water). These creams are particularly suitable in cases of burns, erythema due to the sun rays, rashes, anogenital itching, and insect bites.
Hydrophilic ointment (with excipients such as polyglycols, stearyl alcohol, sodium laurylsulfate, glycerine, water). These ointments are used in the case of burns, erythema caused by sun rays, rashes, anogenital itching, or insect bites.
Viscous solutions, (The excipients may be sodium carboxymethylcellulose in water). These solutions are suitable in case of irritation and inflammation of the oral cavity and the pharynx.
Sprays, (The excipients may be for instance, menthol, cineole, propylene glycol, together with propellants) for broncoscopic use.
Collyrium, (The excipients may be methylcellulose in water) for corneal anaesthesia without mydriasis.
Suppositories (The excipients may be triglycerides of fatty acids or polyethylene glycols to be used in case of hemorrhoids, anal itching, anal and rectum conditions, and tenesmus).
Claims (16)
1. A benzamide of formula I ##STR16## wherein R=CH3, Cl or COOCH3 ;
R' is a member selected from the group of dialkylamine, pyrrolidine, piperidine, and morpholine radicals,
CH2 R' is in position ortho, meta, or para with respect to the carbonyl group;
and salts thereof with a pharmaceutically acceptable acid.
2. A compound according to claim 1 which is the 2,6-dimethylanilide of 2-diethylaminomethylbenzoic acid and a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1 which is the 2,6-dimethylanilide of 3-diethylaminomethylbenzoic acid, and a pharmaceutically acceptable salt thereof.
4. A compound according to claim 1 which is the 2,6-dimethylanilide of 4-diethylaminomethylbenzoic acid and a pharmaceutically acceptable salt thereof.
5. A compound according to claim 1 which is the 2,6-dimethylanilide of 2-pyrrolidinomethylbenzoic acid and a pharmaceutically acceptable salt thereof.
6. A compound according to claim 1 which is the 2,6-dimethylanilide of 3-pyrrolidinomethyl-benzoic acid and a pharmaceutically acceptable salt thereof.
7. A compound according to claim 1 which is the 2,6-dimethylanilide of 4-pyrrolidinomethyl-benzoic acid, and a pharmaceutically acceptable salt thereof.
8. A compound according to claim 1 which is the 2,6-dimethylanilide of 2-piperidinomethyl-benzoic acid and a pharmaceutically acceptable salt thereof.
9. A compound according to claim 1 which is the 2,6-dimethylanilide of 3-piperidinomethyl-benzoic acid and a pharmaceutically acceptable salt thereof.
10. A compound according to claim 1 which is the 2,6-dimethylanilide of 4-piperidinomethyl-benzoic acid, and a pharmaceutically acceptable salt thereof.
11. A compound according to claim 1 which is the 2,6-dimethylanilide of 2-morpholinomethyl-benzoic acid and a pharmaceutically acceptable salt thereof.
12. A compound according to claim 1 which is the 2,6-dimethylanilide of 3-morpholinomethyl benzoic acid, and a pharmaceutically acceptable salt thereof.
13. A compound according to claim 1 which is the 2,6-dimethylanilide of 4-morpholinomethyl benzoic acid, and a pharmaceutically acceptable salt thereof.
14. A compound according to claim 1 which is the 2-chloro-6-methylanilide of 2-diethylaminomethyl-benzoic acid, and a pharmaceutically acceptable salt thereof.
15. A compound according to claim 1 which is 2-carbomethoxy-6-methylanilide of 2-diethylaminomethyl-benzoic acid and a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition exhibiting local anaesthestic or anti-arrhythmic activity in unit dosage form which contains an effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT27919A/79 | 1979-12-07 | ||
| IT27919/79A IT1126509B (en) | 1979-12-07 | 1979-12-07 | BENZIMIDES WITH LOCAL ANESTHETIC AND ANTI-ARRHYTHMIC ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4305940A true US4305940A (en) | 1981-12-15 |
Family
ID=11222591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/207,902 Expired - Lifetime US4305940A (en) | 1979-12-07 | 1980-11-18 | Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4305940A (en) |
| JP (1) | JPS5692255A (en) |
| DE (1) | DE3042687A1 (en) |
| FR (1) | FR2484409A1 (en) |
| GB (1) | GB2064524A (en) |
| IT (1) | IT1126509B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984000545A1 (en) * | 1982-07-26 | 1984-02-16 | American Hospital Supply Corp | Aryl substituted aminomethyl benzene derivatives useful as antiarrhythmic agents |
| US4748184A (en) * | 1982-07-26 | 1988-05-31 | E. I. Du Pont De Nemours And Company | Aryl substituted aminomethyl benzene derivatives having antiarrhythmic utility |
| US4755527A (en) * | 1982-07-26 | 1988-07-05 | E. I. Du Pont De Nemours And Company | Aryl substituted aminomethyl benzene derivatives |
| WO1989002416A1 (en) * | 1985-06-24 | 1989-03-23 | Williams Technologies, Inc. | Integrated coal cleaning process with mixed acid regeneration |
| US4939163A (en) * | 1987-02-18 | 1990-07-03 | Eli Lilly And Company | Anticonvulsant agents |
| US4981866A (en) * | 1987-02-18 | 1991-01-01 | Eli Lilly And Company | Anticonvulsant agents |
| US5958944A (en) * | 1994-04-18 | 1999-09-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzamide compounds and pharmaceutical use thereof |
| US20060045852A1 (en) * | 2004-08-26 | 2006-03-02 | Ortner Gerard T Jr | Materials and methods for tooth surface preparation for dental bonding |
| CN108289882A (en) * | 2015-10-07 | 2018-07-17 | 代表亚利桑那大学的亚利桑那校董会 | CRMP2 SUMOization inhibitor with and application thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4623486A (en) * | 1985-05-29 | 1986-11-18 | Pfizer Inc. | [4-substituted benzoyloxy]-N-substituted-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxides having anti-arthritic activity |
| US4835181A (en) * | 1987-02-18 | 1989-05-30 | Eli Lilly And Company | Anticonvulsant agents using cyano dimethylphenyl benzamides |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2150190A (en) * | 1937-06-29 | 1939-03-14 | Du Pont | Substituted benzanilides and the process for their preparation |
| US2870146A (en) * | 1958-02-10 | 1959-01-20 | Bristol Lab Inc | Therapeutic agents |
| US3433833A (en) * | 1965-07-12 | 1969-03-18 | Warner Lambert Pharmaceutical | Substituted benzanilide |
| US3950393A (en) * | 1973-04-13 | 1976-04-13 | Boehringer Ingelheim Gmbh | Aminobenzyl-amides and salts thereof |
| US3988371A (en) * | 1972-03-09 | 1976-10-26 | Hansl Nikolaus R | Meta-[2-(benzylamino)-ethyl] benzoic acid amides |
| US4097481A (en) * | 1976-11-08 | 1978-06-27 | Riker Laboratories, Inc. | Tertiary amide derivatives of pyrrolidine and piperidine |
| US4158063A (en) * | 1976-01-08 | 1979-06-12 | Hoechst Aktiengesellschaft | Acylamino(alkyl)benzene derivatives and process for preparing them |
-
1979
- 1979-12-07 IT IT27919/79A patent/IT1126509B/en active
-
1980
- 1980-11-12 DE DE19803042687 patent/DE3042687A1/en not_active Withdrawn
- 1980-11-18 US US06/207,902 patent/US4305940A/en not_active Expired - Lifetime
- 1980-11-18 GB GB8036949A patent/GB2064524A/en not_active Withdrawn
- 1980-12-05 FR FR8025889A patent/FR2484409A1/en not_active Withdrawn
- 1980-12-05 JP JP17253980A patent/JPS5692255A/en active Granted
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2150190A (en) * | 1937-06-29 | 1939-03-14 | Du Pont | Substituted benzanilides and the process for their preparation |
| US2870146A (en) * | 1958-02-10 | 1959-01-20 | Bristol Lab Inc | Therapeutic agents |
| US3433833A (en) * | 1965-07-12 | 1969-03-18 | Warner Lambert Pharmaceutical | Substituted benzanilide |
| US3988371A (en) * | 1972-03-09 | 1976-10-26 | Hansl Nikolaus R | Meta-[2-(benzylamino)-ethyl] benzoic acid amides |
| US3950393A (en) * | 1973-04-13 | 1976-04-13 | Boehringer Ingelheim Gmbh | Aminobenzyl-amides and salts thereof |
| US4158063A (en) * | 1976-01-08 | 1979-06-12 | Hoechst Aktiengesellschaft | Acylamino(alkyl)benzene derivatives and process for preparing them |
| US4097481A (en) * | 1976-11-08 | 1978-06-27 | Riker Laboratories, Inc. | Tertiary amide derivatives of pyrrolidine and piperidine |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984000545A1 (en) * | 1982-07-26 | 1984-02-16 | American Hospital Supply Corp | Aryl substituted aminomethyl benzene derivatives useful as antiarrhythmic agents |
| US4562201A (en) * | 1982-07-26 | 1985-12-31 | American Hospital Supply Corporation | Aminomethyl benzanilides |
| US4748184A (en) * | 1982-07-26 | 1988-05-31 | E. I. Du Pont De Nemours And Company | Aryl substituted aminomethyl benzene derivatives having antiarrhythmic utility |
| US4755527A (en) * | 1982-07-26 | 1988-07-05 | E. I. Du Pont De Nemours And Company | Aryl substituted aminomethyl benzene derivatives |
| WO1989002416A1 (en) * | 1985-06-24 | 1989-03-23 | Williams Technologies, Inc. | Integrated coal cleaning process with mixed acid regeneration |
| US4939163A (en) * | 1987-02-18 | 1990-07-03 | Eli Lilly And Company | Anticonvulsant agents |
| US4981866A (en) * | 1987-02-18 | 1991-01-01 | Eli Lilly And Company | Anticonvulsant agents |
| US5958944A (en) * | 1994-04-18 | 1999-09-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzamide compounds and pharmaceutical use thereof |
| US6156766A (en) * | 1994-04-18 | 2000-12-05 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzamide compounds and pharmaceutical use thereof |
| US20060045852A1 (en) * | 2004-08-26 | 2006-03-02 | Ortner Gerard T Jr | Materials and methods for tooth surface preparation for dental bonding |
| CN108289882A (en) * | 2015-10-07 | 2018-07-17 | 代表亚利桑那大学的亚利桑那校董会 | CRMP2 SUMOization inhibitor with and application thereof |
| EP3359151A4 (en) * | 2015-10-07 | 2019-08-14 | Arizona Board of Regents on behalf of the University of Arizona | Crmp2 sumoylation inhibitors and uses thereof |
| US10441586B2 (en) | 2015-10-07 | 2019-10-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | CRMP2 SUMOylation inhibitors and uses thereof |
| US11020391B2 (en) | 2015-10-07 | 2021-06-01 | Arizona Board Of Regents On Behalf Of The University Of Arizona | CRMP2 sumoylation inhibitors and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2484409A1 (en) | 1981-12-18 |
| IT1126509B (en) | 1986-05-21 |
| JPS5692255A (en) | 1981-07-25 |
| IT7927919A0 (en) | 1979-12-07 |
| DE3042687A1 (en) | 1981-08-27 |
| JPS5761731B2 (en) | 1982-12-25 |
| GB2064524A (en) | 1981-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4302465A (en) | Therapeutically active, substituted piperidines and pyrrolidines therapeutic compositions thereof and methods of use thereof | |
| US4305940A (en) | Benzamides with local anaesthetic and antiarrhythmic activity, salts, and method of preparation thereof and pharmaceutical compositions therefrom | |
| US4569801A (en) | Alkylsulfonamidophenylalkylamines | |
| DE69526183T2 (en) | TOPICAL COMPOSITIONS CONTAINING 3-BENZOYLPHENYL ACETIC ACID DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC INFLAMMATORY DISEASES | |
| EP0164865B1 (en) | N-(aminoalkylphenyl)sulfonamides their preparation and therapeutic use | |
| US3891671A (en) | N-(2-pyrrolidyl or piperidyl alkyl)-4-hydroxy benzamides | |
| PL83097B1 (en) | ||
| US4362892A (en) | Hypolipidaemic compounds | |
| DE69311896T2 (en) | AMINOCYCLOHEXYLAMIDES FOR ANTIARRHYTHMIC AND ANESTHETIC USE | |
| US3591634A (en) | N-(tertiary amino-alkyl)-benzamides | |
| US3772308A (en) | Cyclopentanecetamides and cyclopentaneacetonitriles | |
| US3666760A (en) | Iodinated 3-aminobenzamides | |
| HU180139B (en) | Process for preparing 1-phenyl-2-amino-ethanol derivatives | |
| DE2909742A1 (en) | NEW DERIVATIVES OF PHENYL-ALANINE, THEIR PRODUCTION AND THEIR THERAPEUTIC USE | |
| US3723416A (en) | Substituted 2-arylalkyloxy benzamides | |
| US3833733A (en) | Method of anesthetizing a mammal by administration of a substituted 2-aryl-alkyloxy benzamide | |
| US4822778A (en) | Membrane stabilizing phenoxy-piperidine compounds and pharmaceutical compositions employing such compounds | |
| FI78682B (en) | FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA OXIMETRAR. | |
| US3917679A (en) | Quaternary ammonium salts of N-dialkylaminoalkyl-N-(2-indanyl)anilines | |
| US4530923A (en) | N-acetamilide, N-(phenoxy-2-propanol)- and N-(phenylamino-2-propanol)-cyclicamines | |
| US4016284A (en) | Derivatives of 1,3-benzodioxole, the preparation and use thereof | |
| US4242358A (en) | Method of treatment of algiae | |
| DE3207813C2 (en) | ||
| US3766178A (en) | Substituted 2-arylalkyloxy benzamides | |
| US4545996A (en) | N-(4-Acetylaminophenacyl)amine derivatives useful as pharmaceuticals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |